BGB-23339 / BeiGene - LARVOL DELTA

BGB-23339-101: First-in-Human, Single- and Multiple-Ascending Dose and Food-Effect Study of BGB-23339 in Healthy Participants (clinicaltrials.gov) - P1 | N=92 | Completed | Sponsor: BeiGene | Trial completion date: Sep 2022 ➔ Dec 2022

Trial completion date

BGB-23339-101: First-in-Human, Single- and Multiple-Ascending Dose and Food-Effect Study of BGB-23339 in Healthy Participants (clinicaltrials.gov) - P1 | N=92 | Completed | Sponsor: BeiGene | Recruiting ➔ Completed | Trial completion date: Jun 2023 ➔ Sep 2022 | Trial primary completion date: Mar 2023 ➔ Sep 2022

Trial completion • Trial completion date • Trial primary completion date

BGB-23339-101: First-in-Human, Single- and Multiple-Ascending Dose and Food-Effect Study of BGB-23339 in Healthy Participants (clinicaltrials.gov) - P1 | N=115 | Recruiting | Sponsor: BeiGene | Trial completion date: Oct 2022 ➔ Jun 2023 | Trial primary completion date: Oct 2022 ➔ Mar 2023

Trial completion date • Trial primary completion date

BGB-23339-102: Safety, Tolerability, and Pharmacokinetics of BGB-23339 in Healthy Japanese and Caucasian Subjects (clinicaltrials.gov) - P1 | N=0 | Withdrawn | Sponsor: BeiGene | N=32 ➔ 0 | Initiation date: Jun 2022 ➔ Feb 2022 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial initiation date • Trial withdrawal

Safety, Tolerability, and Pharmacokinetics of BGB-23339 in Healthy Japanese and Caucasian Subjects (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: BeiGene

New P1 trial

BeiGene Initiates First-in-Human Phase 1 Clinical Trial of Investigational TYK2 Inhibitor BGB-23339 (Businesswire) - "BeiGene...announced that the first patient has been dosed in a Phase 1 clinical trial of BGB-23339, a potent, allosteric investigational tyrosine kinase 2 (TYK2) inhibitor internally developed by BeiGene scientists...The first-in-human Phase 1 trial (NCT05093270) is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary activity of BGB-23339. The trial is expected to enroll up to 115 healthy volunteers in Australia and/or China."

Trial status • Immunology • Inflammatory Bowel Disease • Psoriasis